BioWorld

Oct. 23, 2002

Avigen Restructures To Stretch Cash Reserves To Five Years

When companies with three years of cash restructure to reduce spending - well, that might suggest they don't like the chances of the financing window opening anytime soon. (BioWorld Today) Read More

CV Therapeutics Reports Positive Phase III Study Of Tecadenoson

Italian Scientists Report Gene Transfer Using Pig Sperm For Human Organ Replacements

Incara Divests Liver Program Via Sale To Vesta Therapeutics

Other News To Note

Enchira's Financial Troubles Now Include Nasdaq Delisting

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...